Odyssey Therapeutics Inc

Finanzas de Odyssey Therapeutics Inc (ODTX)

$19.600

+0.535 (+2.73%)Al cierre

Comparativa sectorial de ODTX

In the context of the broader market, ODTX competes directly with industry leaders such as SGP and JBIO. With a market capitalization of $869.86M, it holds a significant position in the sector. When comparing efficiency, ODTX's gross margin of N/A stands against SGP's N/A and JBIO's N/A. Such benchmarking helps identify whether Odyssey Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Desempeño financiero de Odyssey Therapeutics Inc

The company reported a net loss of $52.8 million in Q2 2026, an increase from $41.2 million in the same quarter last year, reflecting rising R&D expenses.

Financials

FY2026Q2
YoY:
-100.00%
0.00
Total Revenue
FY2026Q2
YoY:
+8.34%
-46.14M
Operating Profit
FY2026Q2
YoY:
+28.02%
-52.79M
Net Income after Tax
FY2026Q2
YoY:
+100.00%
-1.74
EPS - Diluted
FY2026Q2
YoY:
+1.18%
-34.69M
Free Cash Flow
FY2025Q4
YoY:
0.00%
100.00
Gross Profit Margin - %
FY2026Q2
-134.08K
FCF Margin - %
FY2025Q4
YoY:
+143.96%
-5.00K
Net Margin - %

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar